Connect with us
  • Elysium

Stroke news

Robocath: Precision robotics for better outcomes



Robocath has been developing robotic treatment innovations for cardiovascular disease since 2009.

It’s R-One machine has been designed to enable surgeons to remotely perform delicate stent procedures and there are more indications in the pipeline.

Lucien Goffart is CEO of the French medtech company. Before joining Robocath, he spent four years at Boston Scientific in France as director of the Interventional Cardiology and Structural Heart Division.

“The Robocath story started with the R-One for cardiology. But our founder always had in mind to expand the robot’s capabilities for neural interventions,” Goffart says.

“Last year we initiated a carotid treatment trial at a French hospital. That was our first step.”

In carotid stenting, a catheter is used to insert a balloon into a narrowed artery to improve blood flow and reduce the risk of a stroke.

It’s a precise and delicate procedure and only a limited number of hospitals and physicians are capable of performing it.

In November 2021 as part of a clinical trial, Robocath announced its first robotic carotid stenting at Rennes University Hospital using the R-One.

Goffart says:

“For the patient, the most important aspect is the precision of the intervention.

“The robot can move millimetres at a time. So it’s very precise. Being precise means a better treatment for the patient and a better outcome afterwards.

“In the future, we’re going to be able to use the remote technology to treat the patient as soon as they are identified as having a stroke. The intervention will happen faster than what it is today.”

Feedback on the R-One has been positive so far, Goffart says. The machine can be set up in minutes and surgeons who have used it in Europe and South Africa have mastered it within just two or three procedures.

Last week, Robocath announced the conclusion of its safety and efficacy study for robotic coronary angioplasty performed with R-One.

The technique, which follows the principle as carotid stenting, is often used during heart attacks to improve blood flow to the heart. The results of the 62-patient study are set to be published in May.

Goffart says:

“We are also improving our platform and developing new capabilities to treat be able to perform an entire PCI procedure.”